210 related articles for article (PubMed ID: 31759052)
41. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis.
Schilter H; Findlay AD; Perryman L; Yow TT; Moses J; Zahoor A; Turner CI; Deodhar M; Foot JS; Zhou W; Greco A; Joshi A; Rayner B; Townsend S; Buson A; Jarolimek W
J Cell Mol Med; 2019 Mar; 23(3):1759-1770. PubMed ID: 30536539
[TBL] [Abstract][Full Text] [Related]
42. Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cells.
Filla MS; Dimeo KD; Tong T; Peters DM
Exp Eye Res; 2017 Dec; 165():7-19. PubMed ID: 28860021
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells.
Skill NJ; Johnson TS; Coutts IG; Saint RE; Fisher M; Huang L; El Nahas AM; Collighan RJ; Griffin M
J Biol Chem; 2004 Nov; 279(46):47754-62. PubMed ID: 15326185
[TBL] [Abstract][Full Text] [Related]
44. MAGP-1 and fibronectin control EGFL7 functions by driving its deposition into distinct endothelial extracellular matrix locations.
Villain G; Lelievre E; Broekelmann T; Gayet O; Havet C; Werkmeister E; Mecham R; Dusetti N; Soncin F; Mattot V
FEBS J; 2018 Dec; 285(23):4394-4412. PubMed ID: 30338930
[TBL] [Abstract][Full Text] [Related]
45. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen.
Steffensen B; Wallon UM; Overall CM
J Biol Chem; 1995 May; 270(19):11555-66. PubMed ID: 7744795
[TBL] [Abstract][Full Text] [Related]
46. Mass Spectrometry-Based Disulfide Mapping of Lysyl Oxidase-like 2.
Meier AA; Go EP; Moon HJ; Desaire H; Mure M
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682561
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of lysyl oxidase-like 2 overcomes adhesion-dependent drug resistance in the collagen-enriched liver cancer microenvironment.
Gong L; Zhang Y; Yang Y; Yan Q; Ren J; Luo J; Tiu YC; Fang X; Liu B; Lam RHW; Lam KO; Lee AW; Guan XY
Hepatol Commun; 2022 Nov; 6(11):3194-3211. PubMed ID: 35894804
[TBL] [Abstract][Full Text] [Related]
48. Fibronectin Deposition Participates in Extracellular Matrix Assembly and Vascular Morphogenesis.
Hielscher A; Ellis K; Qiu C; Porterfield J; Gerecht S
PLoS One; 2016; 11(1):e0147600. PubMed ID: 26811931
[TBL] [Abstract][Full Text] [Related]
49. Hypoxia preconditioned DPSC-derived exosomes regulate angiogenesis via transferring LOXL2.
Li B; Liang A; Zhou Y; Huang Y; Liao C; Zhang X; Gong Q
Exp Cell Res; 2023 Apr; 425(2):113543. PubMed ID: 36894050
[TBL] [Abstract][Full Text] [Related]
50. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
[TBL] [Abstract][Full Text] [Related]
51. Loss of LOXL2 Promotes Uterine Hypertrophy and Tumor Progression by Enhancing H3K36ac-Dependent Gene Expression.
Lu X; Xin DE; Du JK; Zou QC; Wu Q; Zhang YS; Deng W; Yue J; Fan XS; Zeng Y; Cheng X; Li X; Hou Z; Mohan M; Zhao TC; Lu X; Chang Z; Xu L; Sun Y; Zu X; Zhang Y; Chinn YE
Cancer Res; 2022 Dec; 82(23):4400-4413. PubMed ID: 36197797
[TBL] [Abstract][Full Text] [Related]
52. LOXL2 promotes oncogenic progression in alveolar rhabdomyosarcoma independently of its catalytic activity.
Almacellas-Rabaiget O; Monaco P; Huertas-Martinez J; García-Monclús S; Chicón-Bosch M; Maqueda-Marcos S; Fabra-Heredia I; Herrero-Martín D; Rello-Varona S; de Alava E; López-Alemany R; Giangrande PH; Tirado OM
Cancer Lett; 2020 Apr; 474():1-14. PubMed ID: 31911079
[TBL] [Abstract][Full Text] [Related]
53. Identification and characterization of the promoter of cancer-related gene LOXL2.
Liu X; Liu T; Hu L; Jiang T; Liu H; Wang Y; Lei Y; Zhu J; Bu Y
Exp Cell Res; 2020 Feb; 387(2):111786. PubMed ID: 31870772
[TBL] [Abstract][Full Text] [Related]
54. The Pro-regions of lysyl oxidase and lysyl oxidase-like 1 are required for deposition onto elastic fibers.
Thomassin L; Werneck CC; Broekelmann TJ; Gleyzal C; Hornstra IK; Mecham RP; Sommer P
J Biol Chem; 2005 Dec; 280(52):42848-55. PubMed ID: 16251195
[TBL] [Abstract][Full Text] [Related]
55. Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state.
Zhang X; Wang Q; Wu J; Wang J; Shi Y; Liu M
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):3828-3833. PubMed ID: 29581294
[TBL] [Abstract][Full Text] [Related]
56. Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.
Zaffryar-Eilot S; Marshall D; Voloshin T; Bar-Zion A; Spangler R; Kessler O; Ghermazien H; Brekhman V; Suss-Toby E; Adam D; Shaked Y; Smith V; Neufeld G
Carcinogenesis; 2013 Oct; 34(10):2370-9. PubMed ID: 23828904
[TBL] [Abstract][Full Text] [Related]
57. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.
Chen W; Yang A; Jia J; Popov YV; Schuppan D; You H
Hepatology; 2020 Aug; 72(2):729-741. PubMed ID: 32176358
[TBL] [Abstract][Full Text] [Related]
58. New Functions of Intracellular LOXL2: Modulation of RNA-Binding Proteins.
Eraso P; Mazón MJ; Jiménez V; Pizarro-García P; Cuevas EP; Majuelos-Melguizo J; Morillo-Bernal J; Cano A; Portillo F
Molecules; 2023 May; 28(11):. PubMed ID: 37298909
[TBL] [Abstract][Full Text] [Related]
59. Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy.
Stangenberg S; Saad S; Schilter HC; Zaky A; Gill A; Pollock CA; Wong MG
Sci Rep; 2018 Jun; 8(1):9423. PubMed ID: 29930330
[TBL] [Abstract][Full Text] [Related]
60. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
